

Summary of Analysis Sets  
(All Participants Randomized)

|  | Placebo<br>n (%) | Xanomeline line Low<br>Dose<br>n (%) | Xanomeline line<br>High Dose<br>n (%) |
|--|------------------|--------------------------------------|---------------------------------------|
| Participants in Population                   | 86               | 84                                   | 84                                    |
| Participants included in ITT population      | 86 (100.0)       | 84 (100.0)                           | 84 (100.0)                            |
| Participants included in efficacy population | 79 ( 91.9)       | 81 ( 96.4)                           | 74 ( 88.1)                            |
| Participants included in safety population   | 86 (100.0)       | 84 (100.0)                           | 84 (100.0)                            |